Verve Therapeutics Share Price Today
(NASDAQ: VERV)

Name: Verve Therapeutics Share Price Today (NASDAQ: VERV) - Verve Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Verve Therapeutics share price is $4.59 & ₹392.28 as on 18 Apr 2025, 2.30 'hrs' IST

$4.59

▲

0.08

(1.77%)

Market is closed - opens 7 PM, 21 Apr 2025

View live Verve Therapeutics share price in Dollar and Rupees. Guide to invest in Verve Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Verve Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Verve Therapeutics share price movements

Today's Low: $4.47
Today's High: $4.80
$4.59
2.61%
Downside
Day's Volatility :6.87%
Upside
4.38%
52 Weeks Low: $2.86
52 Weeks High: $9.31
$4.59
37.59%
Downside
52 Weeks Volatility :69.21%
Upside
50.67%

Verve Therapeutics (VERV) Returns

Period	Verve Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-30.14%	-2.8%	0.0%
6 Months	-17.3%	-11.0%	0.0%
1 Year	-30.87%	-1.9%	0.0%
3 Years	-72.98%	-1.5%	-12.9%

Verve Therapeutics (VERV) Key Statistics

in dollars & INR

Previous Close	$4.51
Open	$4.56
Today's High	$4.8
Today's Low	$4.4701
Market Capitalization	$407.6M
Today's Volume	$2.6M
52 Week High	$9.305
52 Week Low	$2.8647
Revenue TTM	$32.3M
EBITDA	$-221.9M
Earnings Per Share (EPS)	$-2.39
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-36.36%

How to invest in Verve Therapeutics Stock (VERV) from India?

It is very easy for Indian residents to invest directly in Verve Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Verve Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Verve Therapeutics or VERV on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Verve Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Verve Therapeutics shares which would translate to 0.186 fractional shares of Verve Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Verve Therapeutics, in just a few clicks!

Returns in Verve Therapeutics (VERV) for Indian investors in Rupees

The Verve Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Verve Therapeutics investment value today

Current value as on today

₹71,468

Returns

₹28,532

(-28.53%)

Returns from Verve Therapeutics Stock

₹30,873 (-30.87%)

Dollar Returns

₹2,341 (+2.34%)

Indian investors sentiment towards Verve Therapeutics (VERV)

239%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Search interest for Verve Therapeutics Stock from India on INDmoney has increased by 239% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Verve Therapeutics

Alphabet Inc
13.91%
BlackRock Inc
8.48%
Bvf Inc
7.78%
Vanguard Group Inc
4.51%
Casdin Capital, LLC
4.50%
Millennium Management LLC
4.41%

Analyst Recommendation on Verve Therapeutics

Rating

Trend

Buy

82%Buy

17%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Verve Therapeutics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Verve Therapeutics Stock (VERV)

What analysts predicted

Upside of 456.43%

Target:

$25.54

Current:

$4.59

Insights on Verve Therapeutics Stock (Ticker Symbol: VERV)

Price Movement
In the last 7 days, VERV stock has moved up by 38.3%
Increasing Revenue
Revenue is up for the last 10 quarters, 929.0K → 13.08M (in $), with an average increase of 24.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -50.13M → -50.03M (in $), with an average increase of 0.2% per quarter
VERV vs ONC (1 yr)
In the last 1 year, Beone Medicines Ltd has given 76.1% return, outperforming this stock by 108.2%
VERV vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 28.9% return, outperforming this stock by 105.1%
Price to Sales
ForVERV every $1 of sales, investors are willing to pay $12.0, whereas for Beone Medicines Ltd, the investors are paying $6.4 for every $1 of sales.

Verve Therapeutics Technicals Summary

Sell

Neutral

Buy

Verve Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Verve Therapeutics (VERV) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Verve Therapeutics Inc	-18.59%	-17.3%	-30.87%	-72.98%	-90.02%
Regeneron Pharmaceuticals, Inc.	-17.1%	-41.85%	-37.2%	-21.74%	-0.85%
Beone Medicines Ltd	-13.12%	5.03%	78.34%	40.23%	43.44%
Vertex Pharmaceuticals Incorporated	-4.76%	2.3%	24.05%	71.43%	78.99%
Alnylam Pharmaceuticals, Inc.	-9.09%	-19.67%	62.43%	39.66%	61.91%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Verve Therapeutics Inc	2.34	NA	NA	-2.66	-0.36	-0.2	NA	5.56
Regeneron Pharmaceuticals, Inc.	14.68	14.68	0.9	41.18	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.09	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.34	17.96	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.81	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Verve Therapeutics Inc	Buy	$407.6M	-90.02%	2.34	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$60.5B	-0.85%	14.68	31.07%
Beone Medicines Ltd	NA	$26.9B	43.44%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$125.7B	78.99%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$30.4B	61.91%	NA	-12.37%

About Verve Therapeutics

Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/or premature coronary artery diseases; VERVE-201, which targets ANGPTL3 and permanently turn off the ANGPTL3 gene in the liver; and VERVE-301, a development candidate that uses a novel in vivo gene editing approach to permanently turn off the LPA gene in the liver to reduce blood Lp(a) levels. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Boston, Massachusetts.

Organization	Verve Therapeutics
Employees	274
CEO	Dr. Sekar Kathiresan M.D.
Industry	Services

Management People of Verve Therapeutics

Name	Title
Dr. Burt A. Adelman M.D.	Co-Founder & Independent Chairman of the Board
Dr. Sekar Kathiresan M.D.	Co-Founder, CEO & Director
Ms. Allison Dorval CPA	CFO & Principal Accounting Officer
Mr. Andrew D. Ashe J.D.	President, COO & General Counsel
Dr. Kiran Musunuru M.D., M.P.H., Ph.D.	Co-Founder
Dr. J. Keith Joung M.D., Ph.D.	Co-Founder
Dr. Anthony Philippakis M.D., Ph.D.	Co-Founder & Scientific Advisory Board Member
Dr. Barry S. Ticho FACC, M.D., Ph.D.	Co-Founder
Mr. Issi Rozen M.B.A.	Co-Founder & Strategic Advisor
Dr. Troy Lister Ph.D.	Chief Scientific Officer

Important FAQs about investing in VERV Stock from India :

What is Verve Therapeutics share price today?

Verve Therapeutics share price today stands at $4.59, Open: $4.56 ; Previous Close: $4.51 ; High: $4.80 ; Low: $4.47 ; 52 Week High: $9.31 ; 52 Week Low: $2.86.

The stock opens at $4.56, after a previous close of $4.51. The stock reached a daily high of $4.80 and a low of $4.47, with a 52-week high of $9.31 and a 52-week low of $2.86.

Can Indians buy Verve Therapeutics shares?

Yes, Indians can invest in the Verve Therapeutics (VERV) from India.

With INDmoney, you can buy Verve Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Verve Therapeutics at zero transaction cost.

How can I buy Verve Therapeutics shares from India?

It is very easy to buy Verve Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Verve Therapeutics (VERV) be purchased?

Yes, you can buy fractional shares of Verve Therapeutics with INDmoney app.

What are the documents required to start investing in Verve Therapeutics stocks?

To start investing in Verve Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.